Literature DB >> 16217363

Health related quality of life after orthotopic neobladder construction and its comparison with normative values in the Japanese population.

Tatsuaki Yoneda1, Hiroyuki Adachi, Shinji Urakami, Hirofumi Kishi, Kazushi Shigeno, Hiroaki Shiina, Mikio Igawa.   

Abstract

PURPOSE: We report the difference in quality of life (QOL) between patients with an orthotopic neobladder and normative values in the age matched Japanese population.
MATERIALS AND METHODS: Between November 1996 and June 2003, 75 patients underwent orthotopic neobladder construction at our institution, of whom 47 males and 9 females were enrolled in this study. A total of 19 patients were excluded because of death or insufficient followup (less than 6 months). Two types of questionnaire, namely the RAND 36-Item Health Survey, version 2 and the Functional Assessment of Cancer Therapy-Bladder Cancer, were mailed to all 56 patients. The 48 patients (86%) who returned the completed forms were included in our analysis. Postoperative QOL was compared with age matched normative values in the control Japanese population.
RESULTS: Overall there was no significant difference in any scale between patients with a neobladder and the age matched control Japanese population. The patient bodily pain score in the seventh decade of life and the role-physical score in those older than 70 years were better than age matched normative values in the Japanese population (p < 0.005 and p < 0.05, respectively). Male patients in the seventh decade of life were more likely to have better QOL in the physical functioning, role-physical and role-emotional subscales in addition to the bodily pain subscale compared to age matched control values (p < 0.05, < 0.05, < 0.001 and < 0.001, respectively). Likewise in male patients older than 70 years role-physical scores remained better than age matched normative values in the Japanese population (p < 0.01). Further analysis of bladder cancer related QOL showed that patients followed more than 24 months were more likely to have a lower incontinence score than those followed less than 24 months (p < 0.05). In addition, the continence related QOL change alone did not affect any health related QOL scales, as analyzed by RAND 36-Intem Health Survey.
CONCLUSIONS: Our study shows that there is no essential difference in health related QOL between patients with a neobladder and the age matched Japanese control population. The current results provide some primary evidence to help in decision making and eliminate potential anxiety about worse QOL after cystectomy.

Entities:  

Mesh:

Year:  2005        PMID: 16217363     DOI: 10.1097/01.ju.0000176455.82079.33

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  5 in total

1.  Assessment of long-term quality of life in patients with orthotopic neobladder followed for more than 5 years.

Authors:  Atsushi Takenaka; Isao Hara; Hideo Soga; Iori Sakai; Tomoaki Terakawa; Mototsugu Muramaki; Hideaki Miyake; Kazushi Tanaka; Masato Fujisawa
Journal:  Int Urol Nephrol       Date:  2010-10-30       Impact factor: 2.370

2.  The negative-balance isolated pelvic perfusion method using ultrahigh-dose cisplatin for invasive bladder cancer with poor risk.

Authors:  Ryoji Kimata; Yukihiro Kondo; Kaoru Nemoto; Satoru Murata; Tatsuo Kumazaki
Journal:  Int J Clin Oncol       Date:  2010-04-21       Impact factor: 3.402

Review 3.  Orthotopic bladder substitution: Surgical aspects and optimization of outcomes.

Authors:  N Thakare; B W Lamb; S Biers
Journal:  BJUI Compass       Date:  2021-09-02

Review 4.  Trends in quality of life reporting for radical cystectomy and urinary diversion over the last four decades: A systematic review of the literature.

Authors:  Karan Rangarajan; Bhaskar K Somani
Journal:  Arab J Urol       Date:  2019-04-14

5.  Health-related quality of life in Japanese patients with bladder cancer measured by a newly developed Japanese version of the Bladder Cancer Index.

Authors:  Takahiro Osawa; John T Wei; Takashige Abe; Michitaka Honda; Shuhei Yamada; Jun Furumido; Hiroshi Kikuchi; Ryuji Matsumoto; Kazushi Hirakawa; Yasuyuki Sato; Yoshihiro Sasaki; Toru Harabayashi; Norikata Takada; Keita Minami; Hiroshi Tanaka; Ken Morita; Akira Kashiwagi; Naoto Miyajima; Tomoshige Akino; Sachiyo Murai; Yoichi M Ito; Shunichi Fukuhara; Katsuhiko Ogasawara; Nobuo Shinohara
Journal:  Int J Clin Oncol       Date:  2020-08-24       Impact factor: 3.402

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.